Program
zolbetuximab
Also written as “Zolbetuximab”, “IMAB362” and “Claudiximab”.
Its studies are mostly in Adenocarcinoma · Stomach Neoplasms · Pancreatic Neoplasms · Adenocarcinoma Of Esophagus, led by Astellas Pharma.
Furthest: phase 4, since Sep 15, 202612 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 127 open or running | phase 4since Sep 15, 2026 | May 18, 2009 | Dec 31, 2026phase 1 · NCT06396091 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2009First study: phase 1 study in Solid TumorsFirst studyNCT00909025 · 15 enrolled · Germany, Latvia
- Sep 6, 2010Phase 2 study in Solid TumorsNCT01197885 · 54 enrolled · Bulgaria, Germany, Latvia and more
- Jun 19, 2012Phase 2 study in CLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionNCT01630083 · 252 enrolled · Bulgaria, Czechia, Germany and more
- Mar 29, 2018Phase 2 study in Stomach NeoplasmsNCT03505320 · 143 enrolled · United States, France, Italy and more
- Apr 12, 2018Phase 3 study in AdenocarcinomaNCT03504397 · 565 enrolled · United States, Australia, Belgium and more
- May 6, 2018No phase study in Stomach NeoplasmsNCT03528629 · 18 enrolled · Japan
- Aug 24, 2018Phase 3 study in AdenocarcinomaNCT03653507 · 507 enrolled · United States, Argentina, Canada and more
- Jan 23, 2019Phase 2 study in Pancreatic NeoplasmsNCT03816163 · 393 enrolled · United States, Australia, Brazil and more
- Sep 10, 2019Phase 1 study in AdenocarcinomaNCT04086758 · 12 enrolled · China
- Apr 30, 2024Phase 1 study in Metastatic Pancreatic AdenocarcinomaNCT06396091 · 12 enrolled · United States
- Mar 27, 2025Phase 3 study in AdenocarcinomaNCT06901531 · 500 planned · United States, Australia, Belgium and more
- Sep 15, 2026Phase 4 study in AdenocarcinomaNCT07829757 · 50 planned
- Oct 16, 2026Primary completion moved from 2026-07-31 to 2026-12-31Date moved laterphase 1 · +5 months · NCT06396091
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Metastatic Pancreatic AdenocarcinomaNCT06396091
- Jun 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT03505320
- Sep 30, 2028Primary completion: phase 3 study in AdenocarcinomaNCT06901531
- Jul 31, 2029Primary completion: phase 4 study in AdenocarcinomaNCT07829757
TargetBeta
CLDN18 →read by rule
“A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
“Claudin-18 binding agent”ChEMBL 37, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07829757Adenocarcinoma | 4 | Not yet recruiting | Jul 31, 2029 | 50 |
| NCT06901531Adenocarcinoma · United States, Australia, Belgium and more | 3 | Recruiting | Sep 30, 2028 | 500 |
| NCT06396091Metastatic Pancreatic Adenocarcinoma · United States | 1 | Active, not recruiting | Dec 31, 2026 | 12 |
| NCT04086758Adenocarcinoma · China | 1 | Completed | Jan 22, 2021 | 12 |
| NCT03816163Pancreatic Neoplasms · United States, Australia, Brazil and more | 2 | Active, not recruiting | Oct 31, 2026 | 393 |
| NCT03653507Adenocarcinoma · United States, Argentina, Canada and more | 3 | Active, not recruiting | Oct 25, 2022 | 507 |
| NCT03528629Stomach Neoplasms · Japan | – | Completed | Jun 9, 2020 | 18 |
| NCT03504397Adenocarcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 9, 2022 | 565 |
| NCT03505320Stomach Neoplasms · United States, France, Italy and more | 2 | Active, not recruiting | Jun 30, 2027 | 143 |
| NCT01630083CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction · Bulgaria, Czechia, Germany and more | 2 | Completed | Jan 31, 2019 | 252 |
| NCT01197885Solid Tumors · Bulgaria, Germany, Latvia and more | 2 | Completed | Aug 13, 2015 | 54 |
| NCT00909025Solid Tumors · Germany, Latvia | 1 | Completed | May 31, 2010 | 15 |
How it is read
Names in the registry
- “zolbetuximab”, 8 entries
- “Zolbetuximab”, 2 entries
- “IMAB362”, 1 entry
- “Claudiximab”, 1 entry
Conditions, from the studies’ own filings
- Adenocarcinoma, 5 studies
- Stomach Neoplasms, 2 studies
- Pancreatic Neoplasms, 1 study
- Adenocarcinoma Of Esophagus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.